Lynn Morris to Antibodies, Neutralizing
This is a "connection" page, showing publications Lynn Morris has written about Antibodies, Neutralizing.
Connection Strength
14,168
-
Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope. J Virol. 2020 01 06; 94(2).
Score: 0,565
-
Measuring the ability of HIV-specific antibodies to mediate trogocytosis. J Immunol Methods. 2018 12; 463:71-83.
Score: 0,516
-
HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes. J Virol. 2018 09 01; 92(17).
Score: 0,513
-
HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. PLoS Pathog. 2018 04; 14(4):e1006987.
Score: 0,501
-
Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses. AIDS. 2017 10 23; 31(16):2199-2209.
Score: 0,485
-
Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies. Immunol Rev. 2017 01; 275(1):217-229.
Score: 0,459
-
Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site. J Virol. 2016 Nov 15; 90(22):10220-10235.
Score: 0,453
-
Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women. AIDS. 2016 Apr 24; 30(7):1005-14.
Score: 0,437
-
HIV broadly neutralizing antibody targets. Curr Opin HIV AIDS. 2015 May; 10(3):135-43.
Score: 0,408
-
Ability to develop broadly neutralizing HIV-1 antibodies is not restricted by the germline Ig gene repertoire. J Immunol. 2015 May 01; 194(9):4371-8.
Score: 0,406
-
Virological features associated with the development of broadly neutralizing antibodies to HIV-1. Trends Microbiol. 2015 Apr; 23(4):204-11.
Score: 0,399
-
Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection. Curr Opin HIV AIDS. 2014 May; 9(3):210-6.
Score: 0,381
-
Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. J Virol. 2013 May; 87(9):4882-94.
Score: 0,350
-
Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med. 2012 Nov; 18(11):1688-92.
Score: 0,343
-
The Antibody Response against HIV-1. Cold Spring Harb Perspect Med. 2012 Jan; 2(1):a007039.
Score: 0,324
-
Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol. 2011 Nov; 85(21):11502-19.
Score: 0,316
-
Specificity of the autologous neutralizing antibody response. Curr Opin HIV AIDS. 2009 Sep; 4(5):358-63.
Score: 0,276
-
Population shift in antibody immunity following the emergence of a SARS-CoV-2 variant of concern. Sci Rep. 2025 Feb 14; 15(1):5549.
Score: 0,201
-
Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance. J Virol. 2025 Feb 25; 99(2):e0173024.
Score: 0,200
-
Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials. PLoS Pathog. 2023 06; 19(6):e1011469.
Score: 0,180
-
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition. Nat Med. 2022 09; 28(9):1924-1932.
Score: 0,169
-
ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection. PLoS Pathog. 2021 11; 17(11):e1010046.
Score: 0,161
-
Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms. Viruses. 2021 07 02; 13(7).
Score: 0,157
-
Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). N Engl J Med. 2021 06 03; 384(22):2161-2163.
Score: 0,154
-
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. PLoS Med. 2020 05; 17(5):e1003117.
Score: 0,145
-
Plant-based production of highly potent anti-HIV antibodies with engineered posttranslational modifications. Sci Rep. 2020 04 10; 10(1):6201.
Score: 0,144
-
Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection. Virology. 2020 07; 546:1-12.
Score: 0,143
-
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. PLoS Med. 2020 02; 17(2):e1003038.
Score: 0,143
-
Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. mSphere. 2020 Jan 29; 5(1).
Score: 0,142
-
Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway. Front Immunol. 2019; 10:2875.
Score: 0,141
-
Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus. J Virol. 2019 04 15; 93(8).
Score: 0,134
-
Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies. J Virol. 2019 03 15; 93(6).
Score: 0,133
-
Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation. Nat Commun. 2018 10 08; 9(1):4136.
Score: 0,130
-
Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection. Cell Host Microbe. 2018 06 13; 23(6):845-854.e6.
Score: 0,126
-
Neutralization tiers of HIV-1. Curr Opin HIV AIDS. 2018 03; 13(2):128-136.
Score: 0,124
-
Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage. PLoS Pathog. 2018 01; 14(1):e1006825.
Score: 0,123
-
HIV-1 superinfection can occur in the presence of broadly neutralizing antibodies. Vaccine. 2018 01 25; 36(4):578-586.
Score: 0,123
-
Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments. J Virol. 2017 10 01; 91(19).
Score: 0,120
-
Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Sci Transl Med. 2017 09 06; 9(406).
Score: 0,120
-
Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope. J Virol. 2017 09 15; 91(18).
Score: 0,120
-
Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. Sci Transl Med. 2017 03 15; 9(381).
Score: 0,116
-
Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. Sci Transl Med. 2017 03 15; 9(381).
Score: 0,116
-
Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathog. 2017 01; 13(1):e1006074.
Score: 0,115
-
Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. EBioMedicine. 2016 Oct; 12:196-207.
Score: 0,112
-
HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms. Retrovirology. 2016 08 30; 13(1):60.
Score: 0,112
-
Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. Clin Vaccine Immunol. 2016 06; 23(6):496-506.
Score: 0,110
-
Effects of Darwinian Selection and Mutability on Rate of Broadly Neutralizing Antibody Evolution during HIV-1 Infection. PLoS Comput Biol. 2016 05; 12(5):e1004940.
Score: 0,110
-
Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS Pathog. 2016 Mar; 12(3):e1005520.
Score: 0,109
-
Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. Cell Rep. 2016 Jan 05; 14(1):43-54.
Score: 0,107
-
Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nat Struct Mol Biol. 2016 Jan; 23(1):81-90.
Score: 0,107
-
New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. J Virol. 2016 01 01; 90(1):76-91.
Score: 0,105
-
Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat Med. 2015 Nov; 21(11):1332-6.
Score: 0,105
-
Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. Cell Host Microbe. 2015 Sep 09; 18(3):354-62.
Score: 0,105
-
Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa. J Infect Dis. 2015 May 01; 211(9):1461-6.
Score: 0,099
-
Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. Cell Host Microbe. 2014 Sep 10; 16(3):304-13.
Score: 0,098
-
A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1. J Biol Chem. 2014 Oct 24; 289(43):29912-26.
Score: 0,097
-
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014 May 01; 509(7498):55-62.
Score: 0,094
-
Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. Virol J. 2013 Dec 02; 10:347.
Score: 0,093
-
Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog. 2013 Oct; 9(10):e1003738.
Score: 0,092
-
Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science. 2013 May 10; 340(6133):751-6.
Score: 0,089
-
Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. Virology. 2012 Nov 25; 433(2):410-20.
Score: 0,085
-
Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med. 2012 Jul 30; 209(8):1469-79.
Score: 0,084
-
The development of CD4 binding site antibodies during HIV-1 infection. J Virol. 2012 Jul; 86(14):7588-95.
Score: 0,083
-
International network for comparison of HIV neutralization assays: the NeutNet report II. PLoS One. 2012; 7(5):e36438.
Score: 0,083
-
Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One. 2011; 6(9):e23532.
Score: 0,080
-
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol. 2011 Oct; 85(19):9998-10009.
Score: 0,079
-
Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site. J Virol. 2011 Sep; 85(17):9039-50.
Score: 0,078
-
Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. J Virol. 2011 Aug; 85(15):7719-29.
Score: 0,078
-
The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol. 2011 May; 85(10):4828-40.
Score: 0,077
-
Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol. 2011 Apr; 85(7):3128-41.
Score: 0,076
-
Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 2009 Sep; 5(9):e1000598.
Score: 0,069
-
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features. Proc Natl Acad Sci U S A. 2024 Jan 23; 121(4):e2308942121.
Score: 0,047
-
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials. Nat Commun. 2023 Dec 14; 14(1):8299.
Score: 0,046
-
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition. EBioMedicine. 2023 Jul; 93:104590.
Score: 0,045
-
Functional HIV-1/HCV cross-reactive antibodies isolated from a chronically co-infected donor. Cell Rep. 2023 02 28; 42(2):112044.
Score: 0,044
-
Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms. Sci Rep. 2022 10 01; 12(1):16473.
Score: 0,043
-
Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies. PLoS Pathog. 2022 09; 18(9):e1010450.
Score: 0,042
-
High-Throughput B Cell Epitope Determination by Next-Generation Sequencing. Front Immunol. 2022; 13:855772.
Score: 0,041
-
Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies. J Virol. 2022 01 26; 96(2):e0164321.
Score: 0,040
-
Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. Hum Vaccin Immunother. 2022 12 31; 18(1):1908030.
Score: 0,039
-
The V2 loop of HIV gp120 delivers costimulatory signals to CD4+ T cells through Integrin a4ß7 and promotes cellular activation and infection. Proc Natl Acad Sci U S A. 2020 12 22; 117(51):32566-32573.
Score: 0,038
-
Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial. BMJ Open. 2020 11 26; 10(11):e042247.
Score: 0,038
-
Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition. Cell Rep. 2020 04 07; 31(1):107488.
Score: 0,036
-
High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. Cell. 2019 12 12; 179(7):1636-1646.e15.
Score: 0,035
-
Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAb lineage. PLoS Pathog. 2019 09; 15(9):e1008005.
Score: 0,034
-
The adjuvant AlhydroGel elicits higher antibody titres than AddaVax when combined with HIV-1 subtype C gp140 from CAP256. PLoS One. 2018; 13(12):e0208310.
Score: 0,033
-
HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth. Cell Host Microbe. 2018 10 10; 24(4):593-599.e3.
Score: 0,032
-
Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection. Sci Transl Med. 2016 09 28; 8(358):358ra125.
Score: 0,028
-
Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. PLoS One. 2016; 11(9):e0161753.
Score: 0,028
-
Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. PLoS Pathog. 2016 07; 12(7):e1005742.
Score: 0,028
-
Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature. 2014 Oct 23; 514(7523):455-61.
Score: 0,025